[REVISION HISTORY]

Bayer pharmaceutical and financial outlook

3 recorded revisions of this situation.

What changed

2026-11-03 21:05 UTC → 2026-11-03 23:48 UTC · added ~~removed~~

Bayer is facing investor scrutiny regarding its ability to balance pharmaceutical innovation with financial performance. In mid October, the company saw progress in its drug development pipeline, specifically with the FDA accepting a supplemental application for Finerenon to treat adults with chronic kidney disease without diabetes. While this follows positive Phase III study results, it does not represent final approval. By early November, the focus shifted toward the company’s third quarter financial results. Bayer reported a 4.1% increase in third-quarter revenue, reaching 10.053 billion euros, and a 6.9% rise in EBITDA before special items to 1.615 billion euros. Despite this growth, the company recorded a net loss of 672 million euros, which was a reduction from the previous year. This loss was primarily driven by asset impairments for the Xofitin brand at 307 million euros and Claritin at 215 million euros. ~~By November 2026, Bayer raised its full-year earnings guidance following~~ Following third-quarter results that exceeded analyst ~~expectations.~~ expectations, Bayer raised its full-year 2026 earnings guidance. The company now expects adjusted EBITDA to fall between 9.8 billion and 10.3 billion euros, up from the previous forecast of 9.6 billion to 10.1 billion euros. This growth was driven by the pharmaceutical division, which saw a 6.4 percent increase in adjusted revenue to 4.68 billion euros, supported by drugs such as Nubeqa and Kerendia. Consequently, Bayer increased its margin forecast for the pharmaceutical sector to a range of 25% to 27%. CEO Bill Anderson noted that the pharmaceutical sector has reached a “turning point in its growth trajectory.” While the company reported a net loss of 672 million euros for the third quarter, it revised its net debt forecast downward by 1 billion euros, targeting approximately 28 to 29 billion euros by year-end. ~~In the Crop Science division, sales reached 3.88 billion euros, though adjusted EBITDA fell by 41.3 percent due to higher costs and regulatory challenges.~~

Versions

Select a version to see what changed compared to the one before it.